

FORM-PTO-1390 (Rev. 10-96)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		017753-094	
INTERNATIONAL APPLICATION NO. PCT/FR97/01412		INTERNATIONAL FILING DATE 29 July 1997	U.S. APPLICATION NO. If known, see 37 C.F.R. 1.51 <b>09/043933</b> Unassigned
			PRIORITY DATE CLAIMED 30 July 1996
TITLE OF INVENTION <b>PHARMACEUTICAL COMPOSITION FOR TREATING PAPILLOMAVIRUS TUMOURS AND INFECTION</b>			
APPLICANT(S) FOR DO/EO/US Jean-Marc BALLOUL; Nadine BIZOUARNE; and Marie-Paule KIENY			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).</p> <p>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ol style="list-style-type: none"> <li><input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li><input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li><input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</li> </ol> <p><input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p><input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <ol style="list-style-type: none"> <li><input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li><input type="checkbox"/> have been transmitted by the International Bureau.</li> <li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li><input type="checkbox"/> have not been made and will not be made.</li> </ol> <p><input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p><input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p><input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p><b>Items 11. to 16. below concern other document(s) or information included:</b></p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</p> <p><input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information:</p>			

PCT/IB/301 Form  
PCT/IB/304 Form  
PCT/RO/101 Form

U.S. APPLICATION NO (If known, see 37 C.F.R. 1.50) Unassigned	INTERNATIONAL APPLICATION NO. PCT/FR97/01412	ATTORNEY'S DOCKET NUMBER 017753-094			
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS			
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Search Report has been prepared by the EPO or JPO ..... \$930 International preliminary examination fee paid to USPTO (37 CFR 1.482) ..... \$720.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$790.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$1070.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$98.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		\$ 930.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30		\$ 0			
Claims	Number Filed	Number Extra	Rate		
Total Claims	23 -20 =	3	X\$22.00	\$ 66.00	
Independent Claims	2 -3 =	0	X\$82.00	\$ 0	
Multiple dependent claim(s) (if applicable)		+ \$270.00	\$ 0		
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$ 996.00			
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).		\$ 0			
<b>SUBTOTAL =</b>		\$ 996.00			
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +		\$ 0			
<b>TOTAL NATIONAL FEE =</b>		\$ 996.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$ 40.00			
<b>TOTAL FEES ENCLOSED =</b>		\$ 1036.00			
		Amount to be: refunded	\$		
		charged	\$		
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1036.00</u> to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>02-4800</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
Norman H. Stepno BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404					
 SIGNATURE Teresa Stanek Rea NAME					
30,427 REGISTRATION NUMBER					

09/043933  
69 Recd PCT/P10 30 MAR 1998

Patent  
Attorney's Docket No. 017753-094

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
Jean-Marc BALLOUL et al. ) Group Art Unit: Unassigned  
Application No.: Unassigned ) Examiner: Unassigned  
(Corresponds to PCT/FR97/01412) )  
International Filing Date: 29 July 1997 )  
For: PHARMACEUTICAL COMPOSITION )  
FOR TREATING PAPILLOMAVIRUS )  
TUMORS AND INFECTION )

**PRELIMINARY AMENDMENT**

**BOX PCT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-captioned application as follows:

**IN THE CLAIMS:**

Please amend the claims as follows:

Kindly cancel claim 22, without prejudice or disclaimer.

Claim 2, line 2, change "characterized in that" to --wherein--.

Claim 3, line 2, change "characterized in that" to --wherein--.

Claim 4, lines 1-2, change "one of Claims 1 to 3, characterized in that" to

--Claim 1, wherein--.

Claim 5, lines 1-2, change "one of Claims 1 to 4, characterized in that" to --Claim 1, wherein--.

Claim 6, line 2, change "characterized in that" to --wherein--.

Claim 7, line 2, change "or 6, characterized in that" to --, wherein--.

Claim 8, lines 1-2, change "one of Claims 1 to 7, characterized in that it comprises" to --Claim 1, comprising--.

Claim 9, lines 1-2, change "one of Claims 1 to 8, characterized in that" to --Claim 1, wherein--.

11. (Amended) Pharmaceutical composition according to Claim 10, [characterized in that] wherein said polypeptides [have the characteristics defined in Claims 2 to 9] are derived from the E6 protein, from the E7 protein or from the E6 and E7 proteins of a papillomavirus.

Claim 12, line 2, change "or 11, characterized in that" to --, wherein--.

Claim 13, line 2, change "characterized in that" to --wherein--.

Claim 14, line 2, change "characterized in that" to --wherein--.

Claim 15, line 2, change "or 14, characterized in that" to --, wherein--.

Claim 16, line 2, change "or 15, characterized in that" to --, wherein--.

Claim 17, line 2, change "or 15, characterized in that" to --, wherein--.

Claim 18, lines 1-2, change "one of Claims 10 to 17" to --Claim 10--.

Claim 19, lines 1-2, change "one of Claims 10 to 17" to --Claim 10--.

Claim 20, lines 1-2, change "one of Claims 10 to 19, characterized in that" to --Claim 10, wherein--.

Claim 21, lines 1-2, change "one of Claims 1 to 20, characterized in that it comprises" to --Claim 1, comprising--.

Kindly add the following claims:

--23. A method for the treatment or prevention of dysplasia or cancer of the neck of the uterus, comprising administering an effective amount of the pharmaceutical composition of claim 1 to a patient in need of such treatment.

--24. A method for the prevention or treatment of a papilloma-virus infection, comprising administering an effective amount of the pharmaceutical composite of claim 1 to a patient in need of such treatment.--

**REMARKS**

Entry of the foregoing Amendment is respectfully requested.

The claims have been amended to eliminate multiple dependency and to place them in better condition for U.S. patent practice.

Application No. Unassigned  
Attorney's Docket No. 017753-094

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Teresa Stanek Rea  
Teresa Stanek Rea  
Registration No. 30,427  
*by Teresa Stanek Rea  
Reg # 35,032*

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: March 30, 1998

Pharmaceutical composition for treating  
papillomavirus tumors and infection

The subject of the present invention is a pharmaceutical composition intended for the treatment or prevention of lesions associated with papillomaviruses and more particularly with human papillomaviruses (HPV) types 16, 18, 31, 33 and 45.

Papillomaviruses are DNA viruses possessing a circular genome of about 7900 base pairs surrounded by a protein capsid. A number of bovine (BPV) and human (HPV) papillomavirus types have been identified and their genome sequenced (Pfister, 1987, in *The papovaviridae : The Papillomaviruses* (Salzman and Howley publishing) Plenum Press, New York, p 1-38). It comprises an early region and a late region. The late region contains two reading frames L1 and L2 which code for the major components of the capsid. The early region contains at least the reading frames E1, E2, E4, E5, E6 and E7. The E1 and E2 expression products regulate viral replication and the expression of the viral genes whereas those of the E5, E6 and E7 regions are involved in the processes of oncogenic transformation of infected cells. Indeed, it has been shown experimentally that the BPV-1 E5 protein can transform cells *in vitro* (Schlegel et al., 1986, *Science* 233, 464-467). The BPV-1 E6 and HPV-16 E7 proteins are involved in the induction and maintenance of oncogenic transformation. The transforming power of E7 has been demonstrated for HPV-16 and HPV-18 (Kanda et al., 1988, *J. Virol.* 62, 610-613; Vousden et al., 1988, *Oncogene Res.* 3, 1-9; Bedell et al., 1987, *J. Virol.* 61, 3635-3640). No function has been demonstrated in E4.

In man, HPVs are associated with pathologies ranging from benign infection of the skin to warts and to malignant tumors. These viruses are highly specific for the epithelium of the epidermis of the genital, oral and respiratory tracts. The epidemiological data strongly suggest the role of certain strains in cancer of the neck

of the uterus and of the lower pathologies, in particular HPV-16 and -18 and to a lesser degree HPV-31, -33 and -45. Cancer of the neck of the uterus is the second cause of female cancer worldwide. According to the WHO, 460,000  
5 new cases are recorded each year, of which at least 200,000 cases are clearly associated with HPV. A series of studies demonstrates the transforming role of these viruses, their specific integration into the genome of neoplastic cells, their gene activity in cancer cells and  
10 the importance of the expression of the E6 and E7 early genes in maintaining the malignant phenotype of HPV-positive neoplastic cells (Monsenego, J. Impact Medecin, March 11, 1994).

Pathological conditions associated with HPV  
15 viruses give rise to a therapeutic problem on account of their persistent and recurrent nature. Many approaches have already been used in the treatment of these diseases, such as surgery, chemotherapy, antiviral agents and immunotherapy.

In this regard, European Patent EP 0,462,187  
20 describes a vaccination approach using papillomavirus early genes to establish immunity against tumors resulting from the integration of the HPV genome into the cellular DNA and in which the capsid proteins are no  
25 longer expressed. Application WO 93/02184 teaches a therapeutic approach based on the use of the capsid antigens as immunogenic agents. These documents do not suggest the possibility of combining the preventive effect offered by the early polypeptides and the curative  
30 effect conferred by the late polypeptides of papillomaviruses to generate compositions suited to all the serious pathological conditions caused by HPVs. Moreover, during the past few years, it has been proposed to use polypeptides having immunostimulatory activity with the  
35 aim of activating the T cells with a result which is beneficial to a greater or lesser degree depending on the pathological conditions targeted (see for example WO 96/11279).

The present invention relates more precisely to

a preparation based on a mixture of antigens from the early and late regions of a papillomavirus or a vector expressing them simultaneously, with the aim of establishing lasting immunity against infected cells. The 5 candidate vaccines provided within the framework of the present invention can be used for preventive purposes (immunoprophylaxy) to limit the development or propagation of viral infection to the neighboring tissues or for curative purposes (immunotherapy) to prevent or reduce 10 tumor progression in infected patients. The use of the capsid antigens will induce the production of antibodies against the antigenic epitopes located at the surface of the viral particles, preventing the infection from becoming established for a lengthy period. The use of the 15 early proteins will make it possible to induce immunity against the cells infected after integration of the viral DNA.

The present invention also provides a preparation combining a polypeptide from a papillomavirus and an 20 immunostimulatory molecule. One of the advantages of such a composition is that it combines the specific immunity induced by the viral antigens and the aspecific immunity induced by the immunostimulatory molecule designed to reinforce the specific response.

25 The aim of the present invention is to make available to the public pharmaceutical compositions allowing the treatment of HPV infections and more particularly serious pathologies such as cancer of the neck of the uterus, having improved efficacy compared 30 with the prior art compositions.

Accordingly, the subject of the present invention is a pharmaceutical composition intended for the treatment or prevention of a papillomavirus infection or tumor, which comprises, as therapeutic agents:

- 35 (1) at least one polypeptide from the early region of a papillomavirus and at least one polypeptide from the late region of a papillomavirus,  
(2) at least one polypeptide from the early region

of a papillomavirus, at least one polypeptide from the late region of a papillomavirus and at least one polypeptide having immunostimulatory activity, or

- 5       (3) at least one polypeptide from an early or late region of a papillomavirus and at least one polypeptide having immunostimulatory activity.

In general, the term polypeptide refers to all or part of the native polypeptide, to a chimeric polypeptide resulting from the fusion of sequences of different origins or to a variant characterized by at least one mutation (deletion, insertion and/or substitution) of an amino acid. More particularly, a polypeptide in use within the framework of the present invention has, in particular, an amino acid sequence whose degree of similarity with the sequence of the native protein is greater than 75%, advantageously greater than 85% and, preferably, greater than 95%. The degree of similarity can be easily calculated with the aid of an appropriate computer program or by aligning the sequences so as to obtain the maximum degree of homology and by counting the number of positions in which the amino acids of the two sequences are found to be identical in relation to the total number of positions. The sequence of the HPV-16 and HPV-18 genomes is disclosed in Genebank with accession numbers K02718 and X05015 respectively.

As recalled earlier, the genome of viruses of the papillomavirus family, in particular BPV and HPV, codes for at least 8 polypeptides, two late polypeptides L1 and L2 comprising the viral capsid and 6 early polypeptides (E1, E2, E4, E5, E6 and E7) involved in the regulation and maintenance of the viral genome and in the transformation of the infected cells.

Although all the early proteins of a papilloma-virus can be used within the framework of the present invention, the choice is made advantageously to use a polypeptide derived from the E6 protein, from the E7 protein or from the E6 and E7 proteins. It may be advantageous to use a nononcogenic variant mutated at the

level of the regions involved in the process of transformation of the infected cells. Such variants are described in the literature (Munger et al., 1989, EMBO J. 8, 4099-4105; Crook et al., 1991, Cell 67, 547-556; Heck 5 et al., 1992, Proc. Natl. Acad. Sci. USA 89, 4442-4446; Phelps et al., 1992, J. Virol. 66, 2418-2427).

A preferred polypeptide from the late region of a papillomavirus is derived from the L1 protein, from the L2 protein or from the L1 and L2 proteins.

10 According to the particularly advantageous embodiments (2) and (3), a composition according to the invention also comprises a polypeptide having an immunostimulatory activity. "Immunostimulatory" is understood to mean the capacity to stimulate a humoral immune 15 response by activating the B lymphocytes so as to amplify the production of antibodies directed against the papillomavirus antigens or to stimulate a cell-mediated immune response by activating the T lymphocytes so as to trigger a significant cytotoxic response against tumor 20 cells or cells infected by a papillomavirus. As a guide, the immunostimulation can be evaluated in an animal model (by comparing the level of rejection in an animal into which a tumor expressing the target antigen has been transplanted, this being in the presence and in the 25 absence of the immunostimulant). More generally, the means for demonstrating an immunostimulation are indicated in Roitt (in *Immunology*, 4th edition, Moby Ltd).

It is possible to use a native immunostimulatory 30 molecule as found in a mammal, and, in particular, in man, a portion thereof, a chimeric molecule obtained from the fusion of sequences of various origins or a mutant, provided, however, the immunostimulatory function is 35 preserved. Among all the molecules which can be envisaged, a polypeptide consisting of or derived from interleukin-2, interleukin-7, interleukin-12 and co-adhesion molecules B7.1 and B7.2 will be preferably used, interleukin-2 and the molecule B7.1 being particularly preferred within the framework of the present invention.

A preferred composition according to the invention comprises:

- (1) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region and a polypeptide from the L2 region of a papillomavirus,
- 5 (2) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus and a polypeptide derived from interleukin-2,
- 10 (3) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus and a polypeptide derived from the molecule B7.1,
- 15 (4) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus, a polypeptide derived from the molecule B7.1 and a polypeptide derived from interleukin-2,
- 20 (5) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus and a polypeptide derived from interleukin-2,
- 25 (6) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus and a polypeptide derived from the molecule B7.1, or
- (7) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus, a polypeptide derived from the molecule B7.1 and a polypeptide derived from interleukin-2.

Given the observations recalled above on the incidence of infection by some HPV types in the cases of cancer of the neck of the uterus, a composition according to the invention comprises a polypeptide from a risk-carrying papillomavirus of the HPV-16, HPV-18, HPV-31, HPV-33 and/or HPV-45 type, and in particular from the HPV-16 virus. Of course, in the case where the composition includes several papillomavirus antigens, they may be of common or different origin.

In general, a polypeptide from a papillomavirus

or having an immunostimulatory activity can be produced by the conventional methods of chemical synthesis or alternatively by recombinant DNA techniques (see for example Maniatis et al., 1989, *Laboratory Manual*, Cold Spring Harbor, Laboratory Press, Cold Spring Harbor, NY). More particularly, a method of preparation comprises the act of culturing a cell transformed with a DNA fragment coding for the polypeptide in question so as to generate a producing cell and the act of harvesting said polypeptide from the culture. The producing cell may be of any origin and without limitation, a bacterium, a yeast or alternatively a mammalian cell, insofar as the DNA fragment considered is either integrated into its genome or integrated into an appropriate expression vector capable of replicating. Of course, the DNA fragment is placed under the control of transcriptional and translational signals allowing its expression in the producing cell. Expression vectors and control signals are known to persons skilled in the art.

The present invention also relates to a pharmaceutical composition intended for the treatment or prevention of a papillomavirus infection or tumor, which comprises, as therapeutic agent(s), one or more recombinant vectors into which there are inserted DNA fragments coding for:

- (1) at least one polypeptide from the early region of a papillomavirus and at least one polypeptide from the late region of a papillomavirus,
  - (2) at least one polypeptide from the early region of a papillomavirus, at least one polypeptide from the late region of a papillomavirus and at least one polypeptide having an immunostimulatory activity, or
  - (3) at least one polypeptide from an early or late region of a papillomavirus and at least one polypeptide having an immunostimulatory activity;
- said DNA fragments being placed under the control of the elements necessary for their expression in a host cell or organism.

According to this alternative which is in fact preferred, the therapeutic agent is a vector into which there are inserted the DNA fragments coding for the polypeptides from a papillomavirus or immunostimulants as defined above. This type of composition has the advantage of cheap production and high stability under a variety of environmental conditions. In particular, the preservation conditions are less constraining.

The DNA fragments coding for a polypeptide from a papillomavirus can be obtained by cloning, by PCR (Polymerase Chain Reaction) or by chemical synthesis according to the conventional techniques commonly used starting with positive papillomavirus cells obtained from patients or from collections.

The gene coding for a polypeptide having immunostimulatory activity can also be isolated according to standard techniques from the genome of a cell (genomic type) or from the messenger RNAs of a cell in which it is expressed (complementary DNA type). Moreover, the gene in question can code for (i) a soluble molecule, which is either intracellular or secreted into the external medium, or (ii) a molecule anchored in the membrane and therefore present at the surface of the cells expressing it.

A preferred recombinant vector within the framework of the invention is a viral vector into whose genome there have been inserted the abovementioned DNA fragments so as to allow their transfer and their expression in a host cell or organism. A viral vector which can be used within the framework of the present invention may be derived in particular from a poxvirus, an adenovirus, a retrovirus, a herpesvirus or an adeno-associated virus. Advantageously, it may be a nonintegrative vector having an attenuated virulence. Such vectors, as well as the techniques for preparing them, are known to persons skilled in the art.

In the case where an adenoviral vector is used, there will be preferably used a vector which is nonreplicative by virtue of the deletion of regions

essential for replication and, in particular, of the majority of the E1 region so as to avoid its propagation within the host organism or the environment. It goes without saying that other regions of the adenoviral genome can be modified or deleted insofar as the defective essential functions are trans-complemented. A preferred adenoviral vector according to the invention will retain the sequences essential for encapsidation, namely the 5' and 3' ITRs (Inverted Terminal Repeat) and the encapsidation region. The various adenoviral vectors as well as the techniques for preparing them are conventional and are described in Graham and Prevec (1991, in *Methods in Molecular Biology*, vol 7, p 109-128; Ed: E.J. Murey, The Human Press Inc.) and in international application WO 94/28152. If a retrovirus is used, the LTRs (Long Terminal Repeat) and the encapsidation sequences will be retained (see for example Naviaux and Verma, 1992, *Current Opinion in Biotechnology* 3, 540-547).

According to an advantageous embodiment, a recombinant viral vector according to the invention is derived from a poxvirus and, in particular, from an avian poxvirus such as the canarypox virus, a fowlpox virus or a vaccinia virus, the latter being preferred. Among all the vaccinia viruses which can be envisaged within the framework of the present invention, the Copenhagen, Wyeth and modified Ankara (MVA for Modified Vaccinia Ankara Virus) strains are preferably chosen. The general conditions for obtaining a vaccinia virus capable of expressing a heterologous gene are taught in European Patent EP 83 286 and application EP 206 920. As for the MVA virus, it is more particularly described in (Mayr et al., 1975, *Infection* 3, 6-14; Sutter and Moss, 1992, *Proc. Natl. Acad. Sci. USA* 89, 10847-10851).

Of course, in the framework of the present invention, the DNA fragments are placed under the control of the elements necessary for their expression. These include the appropriate elements for regulation of transcription as well as signals for initiation and

termination of translation. The promoter is of particular importance. In general, use will be made of a promoter which is functional in the host organism or cell which it is desired to treat and which is suited to the vector used. In addition, it can be modified so as to contain regulatory sequences, for example an element for activating transcription or sequences responding to certain cellular signals. In this regard, it may be advantageous to use a tissue-specific promoter since the lesions associated with papillomaviruses are located at the level of the genital tracts, or a promoter responding to tumor-specific signals (for example which is activated in the presence of growth factors which are generally overexpressed by tumor cells) so as to limit the expression to tumor cells alone.

Among the promoters which can be envisaged within the framework of the invention, there may be mentioned the SV40 (Simian Virus 40) promoters, the HMG (Hydroxy-Methyl-Glutaryl-coenzyme A) promoters, the TK (Thymidine Kinase) promoters, the CMV (cytomegalovirus) promoters, the RSV (Rous Sarcoma Virus) promoters, the adenovirus MLP (Major Late Promoter) promoters which are suited to adenoviral vectors and the Mo-MLV (Moloney Murine Leukemia Virus) LTR promoters which are more specific to retroviral vectors. When the vector is derived from a poxvirus, the promoter will be preferably the promoter of a gene of the poxvirus used, for example the promoter of the gene coding for the protein 7.5K, H5R, TK or K1L of the vaccinia virus. They are described in the literature and can be cloned from the viral genome by conventional techniques.

Moreover, the elements necessary for the expression may also comprise sequences enhancing the expression or maintenance in the host cell (intron, signal sequence, sequence for termination of transcription, site of initiation of translation, sequences modifying the presentation of the polypeptide to the cells of the host's immune system and the like). However, for a vector derived from a poxvirus, the use of introns will be

avoided.

A composition according to the invention can be obtained either with several recombinant vectors, each expressing a given polypeptide, or with a single vector expressing the DNA fragments corresponding to the chosen polypeptides placed under the control of independent or common elements. According to the latter option, there may be used sequences which make it possible to initiate translation internally (IRES) or fusions of the different genes in phase.

The general conditions for obtaining a recombinant vector in use in the present invention are widely described in the state of the art. As regards a poxviral vector, reference may be made to European Patent EP 83 286 the content of which is incorporated herein by reference. These conditions are applicable to the other viruses acceptable as a vector, which possess a non-essential genomic region into which the expression units may be incorporated. Of course, they may be inserted in the same locus or in a different locus. For example, when the Copenhagen strain of a vaccinia virus is used, the preferred site of insertion is the TK locus and/or the K1L locus. The insertion at the level of the viral TK gene has the effect of inactivating it and thus of facilitating the selection of the recombinants. In the context of the MVA strain of a vaccinia virus, the insertion of the immunostimulatory and papillomavirus genes can be carried out within one of the excisions I to VI and, preferably, the excision zone II or III (Meyer et al., 1991, J. Gen. Virol. 72, 1031-1038; Sutter et al., 1994, Vaccine 12, 1032-1040).

In accordance with the objectives pursued by the present invention, a recombinant vector may, in addition, comprise a unit for expression of a selectable marker gene in order to facilitate the steps for isolating and purifying the recombinant virus. There may be mentioned in particular the Neo gene which confers resistance to the antibiotic G418, the pac gene for resistance to puromycin, the herpes simplex virus type 1 (HSV-1) TK

gene which confers sensitivity to certain nucleoside analogs such as ganciclovir or acyclovir, the bacterial genes *LacZ* coding for  $\beta$ -galactosidase and *gus A* coding for  $\beta$ -glucuronidase. The latter two enzymatic markers make it possible to pick out the recombinant viruses by staining in the presence of the substrates X-Gal (5-bromo-4-chloro-3-indolyl  $\beta$ -D-galactopyranoside) and XglcA (5-bromo-6-chloro-3-indolyl  $\beta$ -D-glucoronide) respectively.

A pharmaceutical composition according to the invention for the treatment or prevention of a papillomavirus infection or tumor comprises one or more recombinant vectors derived from the Copenhagen or MVA strain of a vaccinia virus into which there are inserted:

- 15 (1) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus and a DNA fragment coding for the molecule B7.1,
- 20 (2) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus and a DNA fragment coding for interleukin-2,
- 25 (3) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the molecule B7.1 and a DNA fragment coding for interleukin-2,
- 30 (4) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the L1 protein of a papillomavirus and a DNA fragment coding for the L2 protein of a papillomavirus,
- 35 (5) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus and a DNA fragment coding for the molecule B7.1,

- 5           (6) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus and a DNA fragment coding for interleukin-2, or
- 10          (7) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus, a DNA fragment coding for the molecule B7.1 and a DNA fragment coding for interleukin-2.

15          On the other hand, a pharmaceutical composition according to the invention more particularly intended for immunoprophylaxy comprises one or more recombinant vectors derived from the Copenhagen or MVA strain of a vaccinia virus, into which there are inserted:

- 20          (1) a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus and a DNA fragment coding for the molecule B7.1,
- 25          (2) a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus and a DNA fragment coding for interleukin-2, or
- 30          (3) a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus, a DNA fragment coding for interleukin-2 and a DNA fragment coding for the molecule B7.1.

35          A composition according to the invention can be prepared according to methods known in the field of vaccines and the applicable doses may vary within a wide range. They depend in particular on the polypeptides and on the virus used, the pathological condition to be treated, the condition of the patient and other parameters which may be evaluated by the clinician. However,

in general, the dose of virus per kilo will be from  $10^4$  to  $10^{11}$ , advantageously from  $10^6$  to  $10^{10}$  and, preferably, from  $10^7$  to  $10^9$  plaque forming units (pfu) when the therapeutic agent is a viral vector and from 0.05 to 5 500 mg, advantageously from 0.5 to 200 mg and, preferably, from 1 to 100 mg when the therapeutic agent is of polypeptide origin.

A composition according to the invention can be administered by any conventional route of administration, 10 in particular by the intravenous, intramuscular, subcutaneous or subepithelial route, or alternatively by scarification. In the case of an accessible tumor, it is also possible to use direct injection into the site or in the vicinity of the tumor or to use topical application. 15 As a vaccine, a composition according to the invention can be administered according to practices which are common in the field, for example as a single dose or a dose repeated once or several times after a certain time interval. On the other hand, in the context of a curative 20 treatment, it can be administered frequently for a period which is sufficient for the treatment to be effective. When the therapeutic agent is a viral vector, this virus is preferably in a live form. In the case of a poxviral vector, the use of an attenuated strain such as the 25 thymidine kinase negative Copenhagen strain or MVA strain will be preferred. Finally, a recombinant viral vector can be attenuated by an appropriate chemical treatment known to persons skilled in the art. However, injecting a killed recombinant vector can also be envisaged.

According to a preferred embodiment, a pharmaceutical composition according to the invention comprises 30 a therapeutically effective quantity of a recombinant vector in combination with a pharmaceutically acceptable carrier. The carrier is chosen so as to allow its administration by injection into humans or into animals. It 35 may also comprise a vehicle, a diluent and/or an adjuvant and may be provided in liquid or freeze-dried form.

The present invention also relates to a pharmaceutical composition according to the invention, as a

medicament for the treatment or prevention of cancer of the neck of the uterus, of a dysplasia of the neck of low grade and of a papillomavirus infection.

Finally, the present invention also relates to a  
5 method of treating or preventing the abovementioned pathological conditions, according to which a pharmaceutically effective quantity of a mixture of polypeptide or of a recombinant vector in use in the present invention is administered to an individual needing such a  
10 treatment.

The present invention is illustrated by reference to the following figures.

Figure 1 is a diagrammatic representation of the vector pTG5021 allowing the transfer, to the TK locus of  
15 the Copenhagen vaccinia, of the HPV-16 late genes L1 and L2 placed under the control of the promoter p7.5K, the two cassettes being in opposite orientation relative to each other.

Figure 2 is a diagrammatic representation of the vector pTG5065 allowing the transfer, to the K1L locus of the Copenhagen vaccinia, of the HPV-16 early genes E6 and E7 placed under the control of the promoter pH5R (the two cassettes being in opposite orientation relative to each other), of the human IL-2 (IL2h) gene placed under the  
25 control of the promoter p7.5K and of the marker gene LacZ (btaGAL) placed under the control of the promoter pK1L.

Figure 3 diagrammatically illustrates the strategy which can be used to introduce the HPV-16 late genes L1 and L2 into the exclusion zone II of an MVA  
30 vaccinia virus, the left and right recombination arms being indicated (BRG2 and BRD2) respectively.

#### **EXAMPLES**

The present invention is described more fully with the aid of the following examples, without being  
35 limited as a result.

The constructions described below are carried out according to the general genetic engineering and

molecular cloning techniques detailed in Maniatis et al., (1989, *supra*) or according to the manufacturer's recommendations when a commercial kit is used. Synthetic oligonucleotide site-directed mutagenesis *in vitro* is  
5 carried out with the aid of the kit distributed by Amersham. PCR amplification techniques are known to persons skilled in the art (see for example PCR Protocols - A guide to methods and applications, 1990, published by Innis, Gelfand, Sninsky and White, Academic Press Inc.).  
10 As regards the repair of restriction sites, the technique used consists in filling the protruding 5' ends with the aid of the large fragment of DNA polymerase I of *E. coli* (Klenow).

The cloning steps, the recombinant M13 bacteriophages are multiplied on the *E. coli* NM522 strain (Stratagene) in an agar-based minimum medium (7.5% agar) or in a liquid rich LBM medium. The recombinant plasmids carrying the ampicillin resistance gene are replicated in the *E. coli* strains C600 (Stratagene), BJ5183 (Hanahan,  
20 1983, J. Mol. Biol. 166, 557-580) and NM522 on agar or liquid medium supplemented with 100 µg/ml of antibiotic. The BJ5183 strain is preferably used when the cloning is carried out by homologous recombination (Bubeck et al., 1993, Nucleic Acid Res. 21, 3601-3602).

25 The construction of the recombinant vaccinia viruses is carried out according to the conventional technology in the field which is disclosed in the documents already cited and in Mackett et al., (1982, Proc. Natl. Acad. Sci. USA 79, 7415-7419) and Mackett et  
30 al., (1984, J. Virol. 49, 857-864).

**EXAMPLE 1: Construction of the Copenhagen vaccinia virus VVTG5021&5065 expressing the HPV-16 E6, E7, L1 and L2 genes and the human IL-2 gene**

**A. Isolation of the HPV16 L1 and L2 genes**

35 The fragments coding for the L1 and L2 proteins are isolated by PCR from the genomic DNA of Caski cells

(ATCC 1550) according to general prior art techniques. The fragment for amplification, carrying the L1 sequences, is subcloned into the vector M13TG130 (Kieny et al., 1983, Gene 26, 91-99) to give the construct 5 M13TG8171. The sequence of the cloned L1 gene reveals several mutations compared with the sequence contained in Genebank (accession K02718): C in place of an A at position 248, C in place of an A at position 253, G in place of an A at position 537, G in place of a C at 10 position 682, G in place of an A at position 874, insertion of a triplet ACT at position 1393, deletion of a triplet GAT at position 1390. The insertion of the PCR fragment, carrying the L2 sequences, into the vector M13TG6131 leads to M13TG9126. 5 point mutations are 15 observed compared with the sequence disclosed in Genebank: C in place of a T at position 378, A in place of a G at position 691, A in place of a G at position 702, G in place of an A at position 990 and C in place of an A at position 1092. As a guide, the vector M13TG6131 20 is derived from M13TG131 (Kieny et al., 1983, *supra*) by mutation of the internal *Bgl*III site situated outside the multiple cloning sites.

25       B. Construction of the vector pTG5021 for the transfer  
          of the L1 and L2 genes into the TK locus of the  
          genome of the vaccinia virus

The gene coding for the L1 protein is modified by creating a *Bgl*III site upstream of the initiator ATG. The mutated gene is excized from the preceding vector (M13TG8185) by *Bgl*III-*Sac*I digestion and inserted between 30 the *Bam*HI and *Sac*I sites of pTG186-poly. The resulting construct is called pTG4019. The transfer vector pTG186-poly is described in detail in French Patent 2,583,429. It has 10 restriction sites for the insertion of the gene 35 to be transferred and the promoter p7.5K for controlling its expression.

The gene coding for the L2 protein is isolated from M13TG9126 by *Bgl*III-*Hind*III digestion and then cloned

between the *Bam*HI and *Hind*III sites in 3' of the 7.5K promoter. M13TG9127 is obtained into which a *Sal*I site is introduced upstream of the promoter by localized mutagenesis. The expression unit "p7.5K-L2 gene" is  
5 isolated from the mutated vector M13TG9129 and cloned into the *Sac*I site of the transfer vector pTG4019 such that the two cassettes p7.5K-L1 and p7.5K-L2 are in opposite orientation. The construct thus obtained pTG5021 is represented in Figure 1. The expression units are  
10 transferred into the genome of the Copenhagen strain of the vaccinia virus by homologous recombination. The recombinant virus designated VVTG5021 is isolated by selection with 5-bromodeoxyuridine (5BUDR).

C. Isolation of the HPV16 E6 and E7 genes

15 The E6 and E7 genes are isolated from the Caski cell line as described in Examples 2 and 3 of European Patent EP 0,462,187. Two constructs were derived from the clone M13E7/E6 containing the HPV-16 E6 and E7 genes so as to facilitate subsequent cloning steps. The first,  
20 designated M13TG8188, results from the introduction by site-directed mutagenesis of *Pst*I and *Bam*HI sites upstream and downstream, respectively, of the E7 gene, and the second, M13TG8189, comprises a *Pst*I site upstream of the E6 gene. The introduction of point mutations  
25 upstream of an initiator ATG and downstream of a stop codon are within the capability of persons skilled in the art.

The combination of the HPV-16 E7 protein with the product of the retinoblastoma gene has been demonstrated  
30 by various authors (see for example Munger et al., 1989, EMBO J. 8, 4099-4105) and correlated with its transforming power. For obvious safety reasons, a nononcogenic mutant, from which the sequences coding for amino acids 21 to 26 of the native E7 protein which are involved in  
35 the transformation function have been deleted, is generated by site-directed mutagenesis of the vector M13TG8188 with the aid of the oligonucleotide oTG5118

(SEQ ID NO: 1). M13TG9104 is obtained. The mutated E7 gene is designated hereinafter E7\*.

Likewise, it has been demonstrated that the HPV-16 E6 protein could interact with the product of expression of the tumor suppressor gene p53 (Crook et al., 1991, Cell 67, 547-556). The domain involved in this interaction has been clearly defined and is situated between residues 111 to 115 of the native protein. The vector M13TG9125 is generated by mutagenesis of M13TG8189 with the aid of the oligonucleotide oTG5377 (SEQ ID NO: 2). The mutated E6 gene is designated hereinafter E6\*.

D. Construction of the transfer vector pTG5065 carrying the HPV-16 E6 and E7 genes and the human IL-2 gene which are integrated into the K1L locus.

The 5.2 kb EcoRI K fragment of the left end of the Copenhagen vaccinia virus genome (Guillard et al., 1985, J. Virol. 53, 316-318) is cloned into the plasmid pUC8 (Gibco BRL) linearized with EcoRI. The vector thus obtained is then subjected to controlled digestion with BglIII followed by ligation so as to delete an 855 bp fragment coding for the K1L host restriction gene (Guillard et al., 1986, Proc. Natl. Acad. Sci., USA 83, 5573-5577). The 3.4 kb BglIII fragment is isolated from this intermediate construct designated pUC8Khr and then cloned into the BamHI site of the plasmid pUC7 (Gibco BRL). pBAC1 is generated, into which an XhoI adaptor is introduced on the left of the unique BglIII site. After digesting with XhoI and BglIII, a SalI-BglIII fragment carrying the p7.5K vaccinia promoter is inserted. The two EcoRI sites are removed by EcoRI digestion followed by treatment with Klenow and religation. The vector pTG2147 is obtained by introducing into the unique BglIII site a multiple cloning site isolated from the vector p poly II (Lathe et al., 187, Gene 57, 193-201) isolated in the form of a BglIII-BamHI fragment. It therefore comprises the recombination arms allowing insertion into the K1L

locus surrounding the p7.5K promoter followed by the restriction sites.

The E6\* and E7\* genes are cloned downstream of the vaccinia promoter pH5R contained in the vector 5 M13TG9132, to give M13TG9138 and M13TG9139, respectively. As a guide, the vector M13TG9132 comes from the insertion of the promoter of the H5R gene isolated by PCR from the viral genome into the phage M13TG6131.

Moreover, the cDNA coding for human interleukin-2 10 is isolated from the plasmid pTG36 (French Patent 2,583,770), introduced into an intermediate vector and taken out again by *Sall-BamHI* digestion so as to be inserted into the transfer vector pTG2147 targeting the locus K1L. The insertion is made at the level of the *PstI* 15 and *XbaI* sites situated downstream of the promoter p7.5K, with the aid of cloning adaptors. pTG5056 is obtained.

The expression unit pH5R-E6\* is isolated from the 20 vector M13TG9139 in the form of a *BglIII-BamHI* fragment which is introduced into the *BamHI* site of the vector pTG5056. The vector pTG5060 is generated. The expression unit pH5R-E7\* is purified from M13TG9138 and inserted at the *BamHI* site of the vector pTG5060, to give pTG5062. It is indicated that insertion at the K1L locus leads to 25 recombinant viruses having a replication capacity which is reduced or even destroyed in certain cell types. For these reasons, a positive selectable marker is introduced to facilitate identification of the recombinant viruses. The vector pTG5065 results from the cloning, into the 30 *BamHI* site of pTG5062, of an expression cassette "pK1L-LacZ gene" isolated from the plasmid pIV75 (Chen et al., 1993, virology 196, 682-693) by *BglIII-BamHI* cleavage. As visualized in Figure 2, it allows the transfer of the E6\*, E7\* and IL-2 units into the K1L locus of the vaccinia virus.

35 The recombinant vaccinia virus, called VVTG5065, is generated by homologous recombination after transfection of the vector pTG5065 into chicken embryo cells infected with the wild-type Copenhagen vaccinia and picked out by staining under agar with X-Gal. The vaccinia

viruses VVTG5021 and VVTG5065 are used in double infection tests. The double recombinants are selected according to the two markers: formation of blue plaques in the presence of X-Gal and deletion of the TK marker. These,  
5 called VVTG5021&5065, express the units p7.5K-IL-2, pH5R-E6\* and pH5R-E7\* integrated at the K1L locus and the units p7.5K-L1 and p7.5K-L2 integrated at the TK locus.

The expression of the HPV genes can be verified by Western-blot analysis with the aid of appropriate  
10 monoclonal or polyclonal antibodies or by inverse PCR. The production of IL-2 can be evaluated by ELISA test or by CTL test as described in the literature. As a guide, the level of expression in vitro is of the order of 60 ng/ml/10<sup>6</sup> cells infected with 1 pfu/cell and 24h.

15 EXAMPLE 2: Construction of the Copenhagen vaccinia virus expressing the E6 and E7 genes and the human IL-2 gene

The cDNA coding for human interleukin-2 is isolated from the plasmid pTG36 by PstI digestion and  
20 inserted into the PstI site of the plasmid pTG186, giving pTG188. The virus obtained by homologous recombination is called VVTG188.

The E6\* gene is isolated from M13TG9125 in the form of a PstI-BamHI fragment and inserted downstream of  
25 the 7.5K promoter between the PstI and XbaI sites of pTG2147 in the presence of a BamHI-XbaI adaptor, giving pTG5057. The E7\* gene is placed under the control of the H5R vaccinia promoter producing M13TG9138 and the cassette bordered by the BamHI-BglII sites is subcloned  
30 into the BamHI site of pTG5057. pTG5059 is obtained, into whose BamHI site the LacZ selectable marker is inserted under the control of the promoter of the K1L vaccinia gene by BglII-BamHI digestion of the vector pIV75. The resulting construct is designated pTG5061 and the virus generated by homologous recombination with the vaccinia genome VVTG5061.

A recombinant vaccinia virus expressing the E6\*

and E7\* genes integrated at the K1L locus and the human IL-2 gene integrated at the TK locus is obtained by co-infection of chicken embryo cells with the viruses VVTG5061 and VVTG188. As a guide, the latter produces a quantity of IL-2 approximately greater than 400 ng per 10<sup>6</sup> cells infected at 1 pfu per cell for 24h. The doubly recombinant virus is designated VVTG5061&188.

EXAMPLE 3: Construction of a Copenhagen vaccinia virus expressing the E6 and E7 genes, and the gene coding for the human adhesion cofactor B7.1

The cDNA coding for B7.1 is isolated from an mRNA preparation obtained from the Daudi cell line (ATCC CCL-213) by inverse PCR using the primers oTG6353 and oTG6352 (SEQ ID NO: 3 and 4). It is indicated that the sequence of the gene is disclosed in Genebank under accession number M27533. The amplified fragment is cloned between the *Bgl*III and *Eco*RI sites of M13TG6131 leading to M13TG9149 and then between the *Bam*HI and *Eco*RI sites of pTG186. The construct is called pTG5090 and the virus obtained by homologous recombination VVTG5090. A vaccinia virus expressing the HPV-16 E6\* and E7\* genes integrated at the K1L locus and the human B7.1 gene integrated at the TK locus can be obtained by co-infection of chicken embryos with the viruses VVTG5061 and VVTG5090. The recombinant virus is designated VVTG5061&5090.

EXAMPLE 4: Construction of an MVA strain of a vaccinia virus expressing the E6 and E7 genes and the B7.1 gene integrated into the zone of excision III

The MVA virus is derived from the Ankara strain of the vaccinia virus. It is not capable of generating infectious particles on mammalian cells but develops satisfactorily on chicken embryo fibroblasts. Its adaptation to these cells caused the excision of 6 regions which are not essential for its development and its

infectious cycle on this type of cells (disappearance of about 15% of the viral genome; Meyer et al., 1991, J. Gen. Virol. 72, 1031-1038). Exogenous genetic material can be integrated at the level of any of these excision 5 zones. Within the framework of the present invention, excisions II and III, which are located at the level of the *HindIII* restriction fragments N and A respectively, are used (Altenburger et al., 1989, Arch. Virol. 105, 15-27).

10 In a first instance, the vector pTG6019 allowing insertion into the excision zone III of the MVA virus is constructed. The homologous recombination arms on either side of the excision zone III are isolated by PCR from the viral genome (see American Patent US 5,185,146) and 15 the primers oTG7637 and oTG7638 (SEQ ID NO: 5 and 6) for the left arm and oTG7635 and oTG7636 (SEQ ID NO: 7 and 8) for the right arm. The amplified fragments are cloned into the *EcoRI* site of the vector pTG1E, to give pTG6019. The genetic material to be transferred is inserted 20 between the two recombination arms. The vector pTG1E is similar to pTG1H (French Patent 2,583,429) except for the presence of an *EcoRI* adaptor in place of multiple cloning sites.

Firstly, a cassette for expression of the *gus A* 25 marker gene is inserted. The 7.5K promoter is first cloned into the *BamHI* site of pTG6019. pTG6021 is obtained into whose *BamHI* site the *gus A* gene generated in the form of a *BglII-BamHI* fragment is inserted. This can be obtained from the sequence disclosed in the 30 literature. The resulting construct is called pTG6022. The presence of the marker will make it possible to discriminate between the wild-type viruses and the recombinant viruses by detecting the GUS enzymatic activity with the substrate XglcA. A red color reveals 35 the  $\beta$ -glucuronidase activity. However, for the purpose of a clinical application, it may be useful to be able to remove this bacterial marker from the final product after selection of the recombinant viruses. To do this, advantage is taken of the capacity of vaccinia to delete

the sequences between two homologous sites. Accordingly, a second promoter p7.5K is inserted downstream of the *gus A* gene in a sense orientation relative to that which directs its expression. The vector pTG6022 is modified by 5 insertion between the *Bam*HI and *Sac*I sites of a fragment p7.5K provided with cohesive ends, to give pTG6025.

The latter is completed by the insertion of the mutated E6\* and E7\* gene expression cassettes. A new promoter sequence p7.5K is first introduced, this time in 10 antisense orientation relative to the preceding ones. This construct, called pTG6039, therefore comprises the labile GUS cassette "p7.5K → *gus A*-p7.5K→" followed by p7.5K in the opposite orientation. In parallel, the E6\* and E7\* genes are isolated from the vectors M13TG9104 and 15 M13TG9125, respectively, by *Bam*HI and *Pst*I digestion and assembled in opposite orientation with respect to each other at the *Pst*I site of M13TG6131. The whole is taken out in the form of a *Pst*I fragment which is inserted into pTG6039 linearized with this same enzyme. The vector 20 pTG6056 is obtained which contains the following sequences p7.5K → *gus A*-p7.5K → E7\*-E6\* ← p7.5K".

The immunostimulatory gene B7.1 is integrated into the latter construct. To do this, the vector pTG6056 is cleaved with *Hind*III and *Kpn*I before being ligated in 25 the presence of the oligonucleotides oTG10451 and oTG10450 (SEQ ID NO: 9 and 10), to generate pTG6070. The latter will allow the cloning of the expression cassette "pH5R-B7.1" by homologous recombination. To this effect, the B7.1 sequences isolated from M13TG9149 are cloned 30 downstream of the vaccinia promoter pH5R, to form M13TG9184. The *Bgl*II-EcoRI fragment carrying the cassette is integrated into the vector pTG6070 linearized with *Xho*I by homologous recombination in *E. coli*. The vector pTG6079 is obtained which in total comprises the *gus A* 35 marker gene in a "labile" form and the cassettes for expression of the HPV-16 early genes as well as a cassette for the costimulation gene B7.1. The virus generated by homologous recombination with the MVA genome is designated MVATG6079.

The units for expression of the HPV-16 late genes can be inserted into the excision zone II with the aid of the transfer vector pTG6018. It is constructed by inserting into the EcoRI site of pTG1E left and right 5 recombination arms bordering the II excision, which are generated by PCR using the primers oTG7665 and oTG7584 (SEQ ID NO: 11 and 12) and oTG7639 and oTG7640 (SEQ ID NO: 13 and 14). As above, a cassette for expression of a positive marker is integrated between the two arms in 10 order to facilitate the detection of the recombinant viruses, it being possible to remove it after the selection step (Spehner et al., 1990, J. Virol. 64, 527-533). The vector pTG6020 results from the cloning of the LacZ gene placed downstream of the promoter p7.5K into the 15 vector pTG6018 linearized with BamHI. pTG6020 is modified by inserting a sequence p7.5K between its BamHI and SacI sites situated downstream of the LacZ gene. pTG6024 is obtained. The cassettes L1 and L2 can then be introduced according to a strategy as shown in Figure 3.

20 EXAMPLE 5: Construction of an MVA strain of vaccinia virus expressing the E6 and E7 genes, and the IL-2 gene integrated into the excision zone  
III

The same strategy as above is used to introduce 25 the IL-2 gene into the vector pTG6056. After cloning the recombinant oligonucleotides oTG10503 and oTG10502 (SEQ ID NO: 15 and 16) to produce pTG6076, the latter is cleaved with XhoI and the BglIII-EcoRI fragment is prepared from M13TG9185 (pH5R-IL-2) inserted by homologous recombination. The vector pTG6090 thus obtained 30 comprises the gus A marker gene in a "labile" form, the cassettes for expression of the HPV-16 early genes as well as a human IL-2 gene cassette. The recombinant virus obtained by homologous recombination with the MVA genome 35 is designated MVATG6090. The late genes can be integrated into the excision zone II using pTG6018, as indicated above.

EXAMPLE 6: Validation of the vector VVTG5021&5065 in an animal model

A. *Toxicity studies*

Nude mice received  $10^7$  pfu of VVTG5021&5065 or  
5  $10^7$  pfu of wild-type vaccinia virus by the intravenous,  
intramuscular, subcutaneous or intracranial route. Groups  
of 5 mice were formed depending on the type of virus  
injected and the route of administration and the number  
of animals having lesions linked to vaccinia was evaluat-  
10 ed 26 days after the injection. The mice which received  
the recombinant virus showed no lesion regardless of the  
route of administration used, whereas the majority of the  
animals treated with the wild-type vaccinia have lesions  
whose frequency and seriousness depends on the route of  
15 administration. Furthermore, deaths are recorded in the  
case of an intravenous and intracranial injection. These  
data show that VVTG5021&5065 is attenuated compared with  
the wild-type virus and that it does not cause lesions  
even after an intracranial injection.

20 B. *Immunoprophylaxy experiments with VVTG5021&5065*

C57BL6 mice were vaccinated three times by the  
subcutaneous route with  $10^7$  pfu of VVTG5021&5065. Three  
days after the last immunization, these animals are  
challenged with  $10^3$  E7W1 cells implanted subcutaneously.  
25 As a guide, the E7W1 cells are obtained from a murine  
lymphoma line transfected with a vector expressing the  
HPV-16 oncogenic E7 gene. The percentage survival of the  
animals as a function of time is compared to that  
obtained with control mice treated with  $10^7$  pfu of a  
30 nonrecombinant vaccinia virus VVTG186 (derivative of the  
TG186 vector described above). Monitoring of mortality  
shows a difference between the two groups. In the control  
group, 100% of the animals died at D36 whereas 40% of the  
animals vaccinated with VVTG5021&5065 were still alive at  
35 D36 and more than 30% at D51.

Thus, the recombinant viruses expressing HPV antigens and an immunostimulatory gene exhibit antitumor activity against tumor cells expressing the HPV-16 E7 oncogene.

5    C.    *Immunotherapy experiments*

C57BL6 mice are inoculated with  $10^3$  E7W1 cells implanted subcutaneously (D0).  $10^7$  pfu of recombinant viruses are then administered, also subcutaneously at D3 and then D6 and finally D9 and the percentage survival of 10 the animals is determined compared with the control animals which received a nonrecombinant virus. Whereas 15 100% of the control animals died, a notable increase in the survival of the animals injected with a mixture of VVTG5061S5021 and VVTG188 is observed. Similar results are obtained after administration of VVTG5065S5021 and VVTG188.

These immunotherapy experiments were repeated using a different tumor model, BMK16myc cells replacing the E7w1 cells. The BMK16myc cells are kidney cells from 20 newborn mice transfected with the HPV-16 genome and the murine c myc gene. The animals are treated with  $10^7$  MVATG6090 viruses expressing the HPV-16 E6\* and E7\* genes and the human IL-2 gene. Compared with the controls, the treated mice exhibit a delayed tumor growth up to D15.

## **SEQUENCE LISTING**

**(1) GENERAL INFORMATION:**

**(i) APPLICANT:**



(ii) TITLE OF INVENTION: Pharmaceutical composition for  
treating papillomavirus tumors and infection

(iii) NUMBER OF SEQUENCES: 16

**(iv) COMPUTER READABLE FORM:**



20 (2) INFORMATION FOR SEQ ID NO: 1:

**(i) SEQUENCE CHARACTERISTICS:**

- (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- 30                   (A) ORGANISM: Human papillomavirus  
                     (B) STRAIN: HPV-16

(C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG5118 (E7 deleted 21 to 26)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TCTGAGCTGT CATTTAATTG AGTTGTCTCT GGTTGC

36

5 (2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- 10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- 15 (A) ORGANISM: Human papillomavirus
- (B) STRAIN: HPV-16
- (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG5377 (E6 deleted 111 to 115)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

20 TGTCCAGATG TCTTCAGT GGCTTTGAC AG

32

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs
- (B) TYPE: nucleic acid
- 25 (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens  
(C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
5 oTG6353 (PCR gene B7.1)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TCAGCCCCCTG AATTCTGCAG ACACGTGTTAT ACAGG

35

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15 (iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

- 20 (A) ORGANISM: Homo sapiens  
(C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG6352 (PCR gene B7.1)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TTGACCCTAA AGATCTGAAG CCATGGGCCA CAC

33

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- 5 (A) ORGANISM: Vaccinia virus  
(B) STRAIN: Modified Ankara  
(C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG7637 (PCR zone III)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GGGGGGGAAT TCAGTAACT TGACTAAATC TT

32

10 (2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 39 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

- 20 (A) ORGANISM: Vaccinia virus  
(B) STRAIN: Modified Ankara  
(C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG7638 (PCR zone III)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

25 GGGGGGGAT CCGAGCTCAC CAGCCACCGA AAGAGCAAT

39

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

5 (iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Vaccinia virus
- (B) STRAIN: Modified Ankara
- (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG7635 (PCR zone III)

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGGGGGGGAT CCGGAAAGTT TTATAGGTAG TT

32

(2) INFORMATION FOR SEQ ID NO: 8:

15 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

20 (iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Vaccinia virus
- (B) STRAIN: Modified Ankara
- (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG7636 (PCR zone III)

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGGGGGGAAT TCTTGTATT TACGTGAACG

30

(2) INFORMATION FOR SEQ ID NO: 9:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 78 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

10 (iii) ANTI-SENSE: NO

10 (vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG10451

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CTTATACAGG GCGTACACTT TCCCTCTCA ATCTCTCTCG AGTTGTATTT ATTTTCATTT 60

15 TTTAAGTATA GAATAAAA 78

(2) INFORMATION FOR SEQ ID NO: 10:

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

25 (vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG10450

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

AGCTTTTAT TCTATACTTA AAAAATGAAA ATAAATACAA CTCGAGAGAG ATTGAGAAGG 60

GAAAGTGTAC GCCCTGTATA AGGTAC 86

(2) INFORMATION FOR SEQ ID NO: 11:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: DNA (genomic)

10 (iii) HYPOTHETICAL: NO

10 (iii) ANTI-SENSE: NO

15 (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Vaccinia virus
- (B) STRAIN: Modified Ankara
- (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG7665 (PCR zone II)

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATGGTACCGA ATTCCATCTA CCAATTCACTC CAACAAACAT 39

(2) INFORMATION FOR SEQ ID NO: 12:

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: DNA (genomic)

25 (iii) HYPOTHETICAL: NO

25 (iii) ANTI-SENSE: YES

25 (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Vaccinia virus  
(B) STRAIN: Modified Ankara  
(C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG7584 (PCR zone II)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GGCTGCAGGA TCCGAGCTCA TCATGACGTC CTCTGCAATG G

41

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs  
10 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

15 (iii) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Vaccinia virus  
(B) STRAIN: Modified Ankara  
20 (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG7639 (PCR zone II)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GGGGGGGGAT CCTGTGAATC ATCCATTCCA CT

32

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: YES

**(vi) ORIGINAL SOURCE:**

- (A) ORGANISM: Vaccinia virus
  - (B) STRAIN: Modified Ankara
  - (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG7640 (PCR zone II)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

**GGGGGGGAAT TCGTTACTAA ATTGCAAGGA AAT**

33

10 (2) INFORMATION FOR SEQ ID NO: 15:

**(i) SEQUENCE CHARACTERISTICS:**

- (A) LENGTH: 69 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

**(iii) ANTI-SENSE: NO**

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
oTG10503

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CTCAAGTCAG TGTTGAGATG ATGCTTGAC AACTCGAGTT TATTTTCATT TTTTAAGTAT 60

**AGAATAAAA** 69

25 (2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 77 base pairs
  - (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

5 (iii) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: synthetic oligonucleotide  
OTG10502

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

10 AGCTTTTAT TCTATACTTA AAAAATGAAA ATAAACTCGA GTTGTCAAAG CATCATCTCA 60

ACACTGACTT GAGGTAC 77

Claims

1. Pharmaceutical composition intended for the treatment or prevention of a papillomavirus infection or tumor, which comprises, as therapeutic agents:
- 5     (1) at least one polypeptide from the early region of a papillomavirus and at least one polypeptide from the late region of a papillomavirus,
- 10    (2) at least one polypeptide from the early region of a papillomavirus, at least one polypeptide from the late region of a papillomavirus and at least one polypeptide having immunostimulatory activity, or
- 15    (3) at least one polypeptide from an early or late region of a papillomavirus and at least one polypeptide having immunostimulatory activity.
- 20    2. Pharmaceutical composition according to Claim 1, characterized in that the polypeptide from the early region of a papillomavirus is derived from the E6 protein, from the E7 protein or from the E6 and E7 proteins of a papillomavirus.
- 25    3. Pharmaceutical composition according to Claim 2, characterized in that the polypeptide from the early region of a papillomavirus is a nononcogenic variant of the E6 and/or E7 protein of a papillomavirus.
- 30    4. Pharmaceutical composition according to one of Claims 1 to 3, characterized in that the polypeptide from the late region of a papillomavirus is derived from the L1 protein, from the L2 protein or from the L1 and L2 proteins.
- 35    5. Pharmaceutical composition according to one of Claims 1 to 4, characterized in that the polypeptide having an immunostimulatory activity is selected from the group consisting of interleukin-2, interleukin-7, interleukin-12 and the co-adhesion molecules B7.1 and B7.2.
- 40    6. Pharmaceutical composition according to Claim 5, characterized in that the polypeptide having immunostimulatory activity is derived from interleukin-2.

7. Pharmaceutical composition according to Claim 5 or 6, characterized in that the polypeptide having immunostimulatory activity is derived from the molecule B7.1.
- 5 8. Pharmaceutical composition according to one of Claims 1 to 7, characterized in that it comprises:
- (1) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region and a polypeptide from the L2 region of a papillomavirus,
- 10 (2) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus and a polypeptide derived from interleukin-2,
- (3) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus and a polypeptide derived from the molecule B7.1,
- 15 (4) a polypeptide from the E6 region, a polypeptide from the E7 region of a papillomavirus, a polypeptide derived from the molecule B7.1 and a polypeptide derived from interleukin-2,
- 20 (5) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus and a polypeptide derived from interleukin-2,
- 25 (6) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus and a polypeptide derived from the molecule B7.1, or
- (7) a polypeptide from the E6 region, a polypeptide from the E7 region, a polypeptide from the L1 region, a polypeptide from the L2 region of a papillomavirus, a polypeptide derived from the molecule B7.1 and a polypeptide derived from interleukin-2.
- 30
- 35 9. Pharmaceutical composition according to one of Claims 1 to 8, characterized in that the papillomavirus is selected from the HPV-16, HPV-18, HPV-31, HPV-33 and/or HPV-45 types.
10. Pharmaceutical composition intended for the treatment or prevention of a papillomavirus infection or

tumor, which comprises, as therapeutic agent(s), one or more recombinant vectors into which there are inserted DNA fragments coding for:

- (1) at least one polypeptide from the early region of a papillomavirus and at least one polypeptide from the late region of a papillomavirus,
  - (2) at least one polypeptide from the early region of a papillomavirus, at least one polypeptide from the late region of a papillomavirus and at least one polypeptide having an immunostimulatory activity, or
  - (3) at least one polypeptide from an early or late region of a papillomavirus and at least one polypeptide having an immunostimulatory activity;
- said DNA fragments being placed under the control of the elements necessary for their expression in a host cell or organism.

11. Pharmaceutical composition according to Claim 10, characterized in that said polypeptides have the characteristics defined in Claims 2 to 9.

12. Pharmaceutical composition according to Claim 10 or 11, characterized in that the recombinant vector is a viral vector which can be derived from the genome of a virus selected from poxviruses, adenoviruses, retroviruses, herpesviruses and adeno-associated viruses.

13. Pharmaceutical composition according to Claim 12, characterized in that the recombinant vector is derived from a poxvirus selected from the group consisting of vaccinia virus, canarypox virus and fowlpox virus.

14. Pharmaceutical composition according to Claim 13, characterized in that the recombinant vector is derived from a vaccinia virus selected from the Copenhagen, Wyeth and modified Ankara (MVA) strains.

15. Pharmaceutical composition according to Claim 13 or 14, characterized in that the elements essential for the expression of the DNA fragments coding for said polypeptides comprise a promoter of a gene of a vaccinia virus selected from the promoters of the thymidine kinase (TK), 7.5K, H5R and K1L genes.

16. Pharmaceutical composition according to Claim 14

or 15, characterized in that the recombinant vector is derived from a vaccinia virus of the Copenhagen strain and in that the DNA fragments coding for said polypeptides are inserted into the TK locus and/or the K1L locus of said vaccinia virus.

5        17. Pharmaceutical composition according to Claim 14 or 15, characterized in that the recombinant vector is derived from a vaccinia virus of the MVA strain and in that the DNA fragments coding for said polypeptides are 10 inserted at the level of any of the excision zones selected from the I, II, III, IV, V and VI excisions of said vaccinia virus.

15        18. Pharmaceutical composition according to one of Claims 10 to 17, intended for the treatment or prevention of a papillomavirus infection or tumor, characterized in that it comprises one or more recombinant vectors derived from the Copenhagen or MVA strain of a vaccinia virus into which there are inserted:

20        (1) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus and a DNA fragment coding for the molecule B7.1,

25        (2) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus and a DNA fragment coding for interleukin-2,

30        (3) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the molecule B7.1 and a DNA fragment coding for interleukin-2,

35        (4) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the L1 protein of a papillomavirus and a DNA fragment coding for the L2 protein of a papillomavirus,

(5) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7

- protein of a papillomavirus, a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus and a DNA fragment coding for the molecule B7.1,
- 5 (6) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus and a DNA fragment coding for interleukin-2, or
- 10 (7) a DNA fragment coding for the E6 protein of a papillomavirus, a DNA fragment coding for the E7 protein of a papillomavirus, a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus, a DNA fragment coding for the molecule B7.1 and a DNA fragment coding for interleukin-2.
- 15 20. Pharmaceutical composition according to one of Claims 10 to 17, intended for the prevention of a papillomavirus infection or tumor, characterized in that it comprises one or more recombinant vectors derived from the Copenhagen or MVA strain of a vaccinia virus, into which there are inserted:
- 25 (1) a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus and a DNA fragment coding for the molecule B7.1,
- 30 (2) a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus and a DNA fragment coding for interleukin-2, or
- 35 (3) a DNA fragment coding for the L1 protein of a papillomavirus, a DNA fragment coding for the L2 protein of a papillomavirus, a DNA fragment coding for interleukin-2 and a DNA fragment coding for the molecule B7.1.
20. Pharmaceutical composition according to one of

Claims 10 to 19, characterized in that the recombinant vector is alive or killed.

21. Pharmaceutical composition according to one of Claims 1 to 20, characterized in that it comprises a 5 pharmaceutically acceptable carrier allowing its administration by injection into humans or into animals.

22. Pharmaceutical composition according to one of Claims 1 to 21, as a medicament for the treatment or prevention of cancer of the neck of the uterus, of a 10 dysplasia of the neck of low grade and of a papillomavirus infection.

1 / 3




FIG. 1

2 / 3




FIG. 2

3 / 3




FIG. 3

**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY PATENT APPLICATION**

Attorney's Docket No. \_\_\_\_\_

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (if only one name is listed below) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (if more than one name is listed below) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:

PHARMACEUTICAL COMPOSITION FOR TREATING PAPILLOMAVIRUS TUMORS AND  
INFECTION

the specification of which

(check one)

is attached hereto;

was filed on July 29, 1997 as

International Application No. PCT/FR97/01412

and was amended on \_\_\_\_\_;  
(if applicable)

I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE;

I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);

I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than twelve months prior to said application;

I hereby claim foreign priority benefits under Title 35, United States Code Sec. 119 and/or Sec. 365 of any foreign application(s) for patent or inventor's certificate as indicated below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application(s) on which priority is claimed:

COMBINED DECLARATION AND POWER OF ATTORNEY			Attorney's Docket No. 017753-077
COUNTRY/INTERNATIONAL	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
FRANCE	96 09584	30.07.96	YES <u>X</u> NO _____
INTERNATIONAL	PCT/FR97/01412	29.07.1997	YES <u>X</u> NO _____

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

34

William L. Mathis	17,337
Peter H. Smolka	15,913
Robert S. Swecker	19,885
Platon N. Mandros	22,124
Benton S. Duffett, Jr.	22,030
Joseph R. Magnone	24,239
Norman H. Stepno	22,716
Ronald L. Grudziecki	24,970
Frederick G. Michaud, Jr.	26,003
Alan E. Kopecki	25,813
Regis E. Slutter	26,999
Samuel C. Miller, III	27,360

Ralph L. Freeland, Jr.	16,110
Robert G. Mukai	28,531
George A. Hovanec, Jr.	28,223
James A. LaBarre	28,632
E. Joseph Gess	28,510
R. Danny Huntington	27,903
Eric H. Weisblatt	30,505
James W. Peterson	26,052
Teresa Stanek Rea	30,427
Robert E. Krebs	25,885
Robert M. Schulman	31,196

William C. Rowland	30,888
T. Gene Dillahunt	25,423
Anthony W. Shaw	30,104
Patrick C. Keane	32,858
Bruce J. Boggs, Jr.	32,344
William H. Benz	25,952
Peter K. Skiff	31,917
Richard J. McGrath	29,195
Matthew L. Schneider	32,814
Michael G. Savage	32,596
Gerald F. Swiss	30,113

and: \_\_\_\_\_

Address all correspondence to:

Norman H. Stepno  
Burns, Doane, Swecker & Mathis, LLP  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

Address all telephone calls to: Norman H. Stepno

at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR <u>BALLOU Jean-Marc</u>	SIGNATURE	DATE March 3, 1998
RESIDENCE 12 rue des Alouettes - 67380 Lingolsheim / Fr	<i>[Signature]</i>	CITIZENSHIP France
POST OFFICE ADDRESS The same as residence		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY <u>BIZQUARNE Nadine</u>	SIGNATURE	DATE March 3, 1998
RESIDENCE 5 rue de Mutzig - 67300 Schiltigheim / Fr	<i>[Signature]</i>	CITIZENSHIP France
POST OFFICE ADDRESS The same as residence		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY <u>KIENY Marie-Paule</u>	SIGNATURE	DATE March 3, 1998
RESIDENCE 6 allée des Platanes - 67100 Strasbourg / Fr	<i>[Signature]</i>	CITIZENSHIP France
POST OFFICE ADDRESS The same as residence		